More Obesity Setbacks For Amylin And Takeda
This article was originally published in PharmAsia News
Executive Summary
Neither Amylin Pharmaceuticals Inc. nor its Japanese partner Takeda Pharmaceutical Company Limited has had an easy time of late with diabetes and obesity R&D, and the hold on development for their joint obesity combination therapy shows prospects aren't improving for the firms or the field
You may also be interested in...
Takeda/Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Development of a once-promising combination of pramlintide and metreleptin for obesity has been discontinued after a "commercial reassessment," U.S.-based Amylin Pharmaceuticals Inc. and Japan's Takeda Pharmaceutical Company Limited announced Aug. 4
Takeda/Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Development of a once-promising combination of pramlintide and metreleptin for obesity has been discontinued after a "commercial reassessment," U.S.-based Amylin Pharmaceuticals Inc. and Japan's Takeda Pharmaceutical Company Limited announced Aug. 4
Can Bydureon Bounce Back? Amylin's Proposed Cardio Safety Trial Is A Faster Option
If FDA approves the new protocol, a QT prolongation study required to refile Bydureon could commence this quarter.